Bavarian Nordic Appoints Christopher Heery, M.D., as Chief Medical Officer
(Thomson Reuters ONE) -
* Joins Bavarian Nordic from National Cancer Institute
COPENHAGEN, Denmark, September 28, 2016 - Bavarian Nordic A/S (OMX: BAVA, OTC:
BVNRY) today announced the appointment of Dr. Christopher R. Heery, M.D. to the
position of Chief Medical Officer. In this role, Dr. Heery will oversee
preclinical and clinical development of the Company's infectious disease and
immuno-oncology portfolio. He will report to Paul Chaplin, CEO, and will be
based on the east coast of the United States.
Most recently, Dr. Heery was Director of the Clinical Trials Group of the
Laboratory of Tumor Immunology and Biology at the National Cancer Institute
(NCI). He joined the NCI Medical Oncology Branch as a Medical Oncology Fellow in
2009 and also served as an Adjunct Appointment in the Genitourinary Malignancies
Branch. He was also part of the larger effort of the Laboratory of Tumor
Immunology and Biology to create new immunotherapies for the treatment of
cancer.
"It is with great pleasure that I welcome Chris to Bavarian Nordic. Through our
collaborations with the NCI, Chris developed an exceptional understanding of our
programs and our science, which draws from his experience leading key clinical
trials in immunology and oncology. Chris will serve as an essential member of
the team as we continue to progress our pipeline of immune-oncology and
infectious disease vaccine candidates," said Paul Chaplin, President and CEO of
Bavarian Nordic.
"I am pleased to join Bavarian Nordic and look forward to continuing to build
the Company's core collaborations and advancing its portfolio of promising
immunotherapies across multiple challenging disease areas with the potential to
significantly impact patient care," said Dr. Heery.
Dr. Heery is board certified in Medical Oncology and Internal Medicine and
received his M.D. from East Carolina University Brody School of Medicine in
2006. He completed his internal medicine residency at the University of Illinois
at Chicago in 2009. Dr. Heery received his undergraduate degree from Duke
University.
The appointment of Dr. Heery does not change the current composition of
Bavarian's Nordic Executive Management.
About Bavarian Nordic
Bavarian Nordic is a fully integrated biotechnology company focused on the
development, manufacturing and commercialization of cancer immunotherapies and
vaccines for infectious diseases, based on the Company's live virus vaccine
platform. Through long-standing collaborations, including a collaboration with
the U.S. government, Bavarian Nordic has developed a portfolio of vaccines for
infectious diseases, including the non-replicating smallpox vaccine,
IMVAMUNE(®), which is stockpiled for emergency use by the United States and
other governments. The vaccine is approved in the European Union (under the
trade name IMVANEX(®)) and in Canada. Bavarian Nordic and Janssen are developing
an Ebola vaccine regimen, which was fast-tracked, with the backing of worldwide
health authorities, and a vaccine for the prevention and treatment of HPV.
Additionally, in collaboration with the National Cancer Institute, Bavarian
Nordic has developed a portfolio of active cancer immunotherapies, including
PROSTVAC(®), which is currently in Phase 3 clinical development for the
treatment of advanced prostate cancer. The company has partnered with Bristol-
Myers Squibb for the potential commercialization of PROSTVAC. For more
information visit www.bavarian-nordic.com or follow us on Twitter
(at)bavariannordic.
Forward-looking statements
This announcement includes forward-looking statements that involve risks,
uncertainties and other factors, many of which are outside of our control, that
could cause actual results to differ materially from the results discussed in
the forward-looking statements. Forward-looking statements include statements
concerning our plans, objectives, goals, future events, performance and/or other
information that is not historical information. All such forward-looking
statements are expressly qualified by these cautionary statements and any other
cautionary statements which may accompany the forward-looking statements. We
undertake no obligation to publicly update or revise forward-looking statements
to reflect subsequent events or circumstances after the date made, except as
required by law.
Contacts
Rolf Sass Sørensen
Vice President Investor Relations (EU)
Tel: +45 61 77 47 43
Seth Lewis
Vice President Investor Relations (US)
Tel: +1 978 341 5271
Press Release
2016-09-28-en:
http://hugin.info/100065/R/2045109/763835.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Bavarian Nordic A/S via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 28.09.2016 - 13:00 Uhr
Sprache: Deutsch
News-ID 497613
Anzahl Zeichen: 5488
contact information:
Town:
Kvistgård
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 177 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Bavarian Nordic Appoints Christopher Heery, M.D., as Chief Medical Officer"
steht unter der journalistisch-redaktionellen Verantwortung von
Bavarian Nordic A/S (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
